Hematology/Oncology Specialist - Orlando, FL

INVESTOR ALERT: Pomerantz law Firm investigates claims on behalf of investors of Karyopharm Therapeutics Inc. - KPTI. Aug 06, 2026, 23:02 ET NEW YORK, Aug. 6, 2026 /PRNewswire/ - Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Karyopharm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 17, 2026, Karyopharm disclosed in a filing with the U.S. Securities and Exchange Commission the implementation of "a retention program for certain employees of the Company, including each of the Company's named executive officers and the Chief Financial Officer", under which top Karyopharm executives will receive "lump sum cash retention awards" ranging from $625,000 to $1,725,000. On this news, Karyopharm's stock price fell $2.04 per share, or 21.45%, to close at $7.47 per share on July 20, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. SOURCE Pomerantz LLP

KPTI stock crashes as trial fails and legal risk mounts. BRYCE TUOHEY - UPDATED JUL. 31, 2026, 9:19 AM ET Karyopharm Therapeutics Inc. faces intensified pressure as pivotal clinical trial setbacks emerge while stocks have been trading down by -69.61 percent Key takeaways. * Phase 3 XPORT-EC-042 selinexor maintenance trial in TP53 wild-type endometrial cancer missed its primary progression-free survival endpoint despite a numerical benefit in a select subgroup. * After the negative data, Karyopharm Therapeutics Inc. plans to cut spending on endometrial cancer and refocus on myelofibrosis and multiple myeloma programs. * KPTI shares plunged about 69% after the XPORT-EC-042 failure, signaling a major reset in how traders value the company's pipeline. * A 2026 Leadership Cash Retention Program for top executives coincided with roughly a 21%-27% slide in KPTI's share price. * Pomerantz LLP has launched a securities-fraud investigation tied to Karyopharm's large executive cash retention program and the sharp stock decline. Live Update At 09:18:46 EDT: On Friday, July 31, 2026 Karyopharm Therapeutics Inc. stock [NASDAQ: KPTI] is trending down by -69.61%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. KPTI is trading like a textbook high-risk biotech after a major blow. The recent daily chart shows Karyopharm Therapeutics Inc. sliding from the $10.00-$10.70 area down toward the mid-$6.00-$7.00 range, a steep multi-day fade ahead of the latest trial news. That kind of downtrend tells traders the market was already nervous about KPTI's pipeline and cash runway. Fundamentals back up that fear. Karyopharm reported about $35.1M in quarterly revenue on total revenue of $35.1M and a gross margin near 96%, but profitability is deeply negative. Operating income came in around -$26.8M, with net income at about -$22.4M for the quarter. Profit margins are heavily in the red, with return on assets also sharply negative. For active traders, that screams "dependent on capital markets." The balance sheet shows roughly $90.9M in cash and cash equivalents against total liabilities of about $397.1M and a current ratio near 1.1. KPTI did raise cash via stock issuance, bringing in more than $20.2M, but free cash flow was still around -$22.7M. On intraday charts, the current $2.00-$2.40 premarket band reflects a stock that has been repriced dramatically lower, with tight, reactive trading as headlines hit. For Karyopharm Therapeutics Inc., survival and future data now matter more than traditional valuation metrics. Why traders are laser-focused on KPTI now. This past week turned KPTI from a quiet biotech into a battlefield ticker. The catalyst was the Phase 3 XPORT-EC-042 readout, where selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer failed to meet its primary endpoint of progression-free survival versus placebo. For a late-stage trial, that's a big deal. The company did report a 5.3-month numerical improvement in progression-free survival in a modified intent-to-treat subgroup, but the market trades on hard endpoints, not hints. When Karyopharm Therapeutics Inc. confirmed the miss, traders reacted fast. Shares of KPTI plunged about 69% once the failure became public, a sign that the market viewed this program as a major piece of the bull thesis. That kind of collapse doesn't just shave off some optimism; it resets how funds think about dilution, deal-making, and the odds of future success across the pipeline. Karyopharm responded by saying it will reduce investment in endometrial cancer and reallocate resources toward myelofibrosis and multiple myeloma programs. The company also emphasized that other selinexor studies in different indications are unaffected. For nimble traders, that creates a classic "broken story, but not dead" setup. The endometrial cancer bet clearly cracked, but KPTI still has remaining shots on goal. Layered on top of the clinical hit is a messy governance and legal narrative. Earlier, Karyopharm Therapeutics Inc. adopted a 2026 Leadership Cash Retention Program, granting sizable lump-sum awards to top executives and its CFO. The market hated it. KPTI fell roughly 21%-27% after the disclosure, sparking outrage around cash going to management while the business bleeds. Now Pomerantz LLP is investigating potential securities fraud and other unlawful practices tied to that program and the stock's sharp drop. For short-term trading, that legal overhang acts like a lid on any sharp bounce, because every spike invites sellers who want out before the next headline. Conclusion. For active traders who live on volatility, KPTI now checks every box: huge gap down, shaken confidence, legal noise, and a binary-feeling pipeline narrative. Karyopharm Therapeutics Inc. still has cash, revenue, and other selinexor programs, but the failed XPORT-EC-042 trial and the 69% plunge changed how the market treats every press release from here. Short term, KPTI is a classic "trade the reaction, not the story" name. The daily downtrend from $10+ into the single digits, and the premarket action around $2, show how aggressive funds have been dumping. Any push into former support levels around $6-$8 now risks turning into resistance as trapped holders sell into strength. Meanwhile, the 2026 Leadership Cash Retention Program and the Pomerantz LLP investigation hang over the tape, adding uncertainty every time Karyopharm Therapeutics Inc. tries to stabilize. For those studying this as a case study, focus on the process: rapid repricing after a Phase 3 failure, the role of governance headlines, and how volume floods into a collapsing chart. As Tim Sykes loves to remind traders, "The market doesn't care about your opinion; it cares about catalysts and price action. Study both, and always, always cut losses quickly." As millionaire penny stock trader and teacher Tim Sykes, says, "Consistency is key in trading; don't let emotions dictate your trades.". KPTI is now a live example of why that rule matters. This article is for educational and research purposes only and is not investment advice. This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Its content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to Millionaire Media, LLC. for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize its news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities. Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles: Once you've got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market's twists and turns. Dig into StocksToTrade's watchlists here: One-of-a-kind AI play revealed. If you'd put $2,000 into Nvidia back in 2020, you'd be sitting on more than $30,000 today. The stock's been an absolute monster... But if you think you missed the boat, then you need to see this urgent message TODAY. Because not only am I revealing why the REAL AI boom is only just getting started... I'm also going to show you my top AI recommendation that's been CRUSHING it in this market. It has nothing to do with Nvidia... or Meta... or OpenAI... or anything else you're probably thinking. It's a unique AI play I'm certain you're not hearing from anyone else... One that could give you the chance to target an entire YEAR of peak Nvidia potential... In just one day. How much has this post helped you? (0 votes, average: 0 out of 5)

Karyopharm Therapeutics' shares plunged 69% in after-hours trading Thursday after its drug selinexor failed a late-stage endometrial cancer trial. The study tested selinexor as maintenance treatment against placebo in patients with advanced or recurrent endometrial cancer but did not show statistically significant delay in disease progression. One patient subgroup showed a trend toward longer progression-free survival—roughly 13 months versus 7.5 months on placebo—but this fell short of required thresholds. The company will reduce spending on its endometrial cancer programme whilst completing data review. Chief Executive Richard Paulson said the company remains focused on its myelofibrosis programme. Karyopharm plans to submit a US FDA application in August seeking accelerated approval for selinexor combined with ruxolitinib for myelofibrosis treatment.